FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149309054> ?p ?o ?g. }

• W2149309054 endingPage "1481.e2" @default.
• W2149309054 startingPage "1474" @default.
• W2149309054 abstract "Background & AimsFew agents are available for the treatment of inflammatory bowel diseases, and patients frequently become unresponsive to biologics. We investigated the feasibility of reinitiating infliximab therapy for patients who previously received only episodic therapy with, lost response to, or had infusion reactions to infliximab. We also aimed to identify factors associated with the success and safety of restarting infliximab, such as antibodies to infliximab and trough levels of the drug.MethodsFrom the inflammatory bowel disease biobank, we identified 128 consecutive patients (105 patients with Crohn's disease, 23 patients with ulcerative colitis) who restarted infliximab after a median 15-month discontinuation (range, 6–125 mo; 28 patients for loss of response or infusion reactions, 100 patients for remission or pregnancy). We also analyzed serum samples that had been collected during the first period of infliximab therapy (T-1), when therapy was reinitiated (T0), and at later time points (T+1, T+2) for trough levels and antibodies to infliximab. We investigated correlations among response to treatment, infusion reactions, treatment modalities, trough levels, and antibodies to infliximab.ResultsReinitiation of infliximab therapy produced a response in 84.5% of patients at week 14, 70% of patients at 1 year, and in 61% of patients at more than 4 years. Fifteen patients had acute infusion reactions and 10 patients had delayed infusion reactions. The absence of antibodies to infliximab at T+1 (hazard ratio [HR], 0.14; 95% confidence interval [CI], 0.026–0.74; P = .021) and reinitiation with concomitant immunomodulator therapy were associated with short-term responses (HR, 6.0; 95% CI, 1.3–27; P = .019). Pregnancy or remission as reason for discontinuation (HR, 2.70; 95% CI, 1.09–6.67; P = .033) and higher trough levels at T+1 (HR, 2.94; 95% CI, 1.18–7.69; P = .021) were associated with long-term response. Undetectable antibodies to infliximab at T+1 were associated with the safety of reinitiating therapy (HR for infusion reaction with detectable antibodies to infliximab, 7.7; 95% CI, 1.88–31.3; P = .004).ConclusionsReinitiating infliximab therapy can be safe and effective for patients with Crohn's disease or ulcerative colitis after a median 15-month discontinuation period. Few agents are available for the treatment of inflammatory bowel diseases, and patients frequently become unresponsive to biologics. We investigated the feasibility of reinitiating infliximab therapy for patients who previously received only episodic therapy with, lost response to, or had infusion reactions to infliximab. We also aimed to identify factors associated with the success and safety of restarting infliximab, such as antibodies to infliximab and trough levels of the drug. From the inflammatory bowel disease biobank, we identified 128 consecutive patients (105 patients with Crohn's disease, 23 patients with ulcerative colitis) who restarted infliximab after a median 15-month discontinuation (range, 6–125 mo; 28 patients for loss of response or infusion reactions, 100 patients for remission or pregnancy). We also analyzed serum samples that had been collected during the first period of infliximab therapy (T-1), when therapy was reinitiated (T0), and at later time points (T+1, T+2) for trough levels and antibodies to infliximab. We investigated correlations among response to treatment, infusion reactions, treatment modalities, trough levels, and antibodies to infliximab. Reinitiation of infliximab therapy produced a response in 84.5% of patients at week 14, 70% of patients at 1 year, and in 61% of patients at more than 4 years. Fifteen patients had acute infusion reactions and 10 patients had delayed infusion reactions. The absence of antibodies to infliximab at T+1 (hazard ratio [HR], 0.14; 95% confidence interval [CI], 0.026–0.74; P = .021) and reinitiation with concomitant immunomodulator therapy were associated with short-term responses (HR, 6.0; 95% CI, 1.3–27; P = .019). Pregnancy or remission as reason for discontinuation (HR, 2.70; 95% CI, 1.09–6.67; P = .033) and higher trough levels at T+1 (HR, 2.94; 95% CI, 1.18–7.69; P = .021) were associated with long-term response. Undetectable antibodies to infliximab at T+1 were associated with the safety of reinitiating therapy (HR for infusion reaction with detectable antibodies to infliximab, 7.7; 95% CI, 1.88–31.3; P = .004). Reinitiating infliximab therapy can be safe and effective for patients with Crohn's disease or ulcerative colitis after a median 15-month discontinuation period." @default.
• W2149309054 created "2016-06-24" @default.
• W2149309054 creator A5019474609 @default.
• W2149309054 creator A5022022076 @default.
• W2149309054 creator A5032111173 @default.
• W2149309054 creator A5033719787 @default.
• W2149309054 creator A5052113690 @default.
• W2149309054 creator A5052596220 @default.
• W2149309054 creator A5065621943 @default.
• W2149309054 creator A5080135700 @default.
• W2149309054 creator A5082317019 @default.
• W2149309054 date "2014-09-01" @default.
• W2149309054 modified "2023-10-11" @default.
• W2149309054 title "Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy" @default.
• W2149309054 cites W1515981258 @default.
• W2149309054 cites W1975218841 @default.
• W2149309054 cites W1985485048 @default.
• W2149309054 cites W1997999969 @default.
• W2149309054 cites W1999488981 @default.
• W2149309054 cites W2018178851 @default.
• W2149309054 cites W2030638161 @default.
• W2149309054 cites W2056596058 @default.
• W2149309054 cites W2059843231 @default.
• W2149309054 cites W2087663450 @default.
• W2149309054 cites W2095161324 @default.
• W2149309054 cites W2106072130 @default.
• W2149309054 cites W2113674146 @default.
• W2149309054 cites W2129027407 @default.
• W2149309054 cites W2141139109 @default.
• W2149309054 cites W2146963207 @default.
• W2149309054 doi "https://doi.org/10.1016/j.cgh.2014.01.033" @default.
• W2149309054 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24486408" @default.
• W2149309054 hasPublicationYear "2014" @default.
• W2149309054 type Work @default.
• W2149309054 sameAs 2149309054 @default.
• W2149309054 citedByCount "110" @default.
• W2149309054 countsByYear W21493090542014 @default.
• W2149309054 countsByYear W21493090542015 @default.
• W2149309054 countsByYear W21493090542016 @default.
• W2149309054 countsByYear W21493090542017 @default.
• W2149309054 countsByYear W21493090542018 @default.
• W2149309054 countsByYear W21493090542019 @default.
• W2149309054 countsByYear W21493090542020 @default.
• W2149309054 countsByYear W21493090542021 @default.
• W2149309054 countsByYear W21493090542022 @default.
• W2149309054 countsByYear W21493090542023 @default.
• W2149309054 crossrefType "journal-article" @default.
• W2149309054 hasAuthorship W2149309054A5019474609 @default.
• W2149309054 hasAuthorship W2149309054A5022022076 @default.
• W2149309054 hasAuthorship W2149309054A5032111173 @default.
• W2149309054 hasAuthorship W2149309054A5033719787 @default.
• W2149309054 hasAuthorship W2149309054A5052113690 @default.
• W2149309054 hasAuthorship W2149309054A5052596220 @default.
• W2149309054 hasAuthorship W2149309054A5065621943 @default.
• W2149309054 hasAuthorship W2149309054A5080135700 @default.
• W2149309054 hasAuthorship W2149309054A5082317019 @default.
• W2149309054 hasBestOaLocation W21493090541 @default.
• W2149309054 hasConcept C126322002 @default.
• W2149309054 hasConcept C141071460 @default.
• W2149309054 hasConcept C207103383 @default.
• W2149309054 hasConcept C2777138892 @default.
• W2149309054 hasConcept C2778260677 @default.
• W2149309054 hasConcept C2778715236 @default.
• W2149309054 hasConcept C2779134260 @default.
• W2149309054 hasConcept C2779384505 @default.
• W2149309054 hasConcept C2780479503 @default.
• W2149309054 hasConcept C2909675724 @default.
• W2149309054 hasConcept C2911091166 @default.
• W2149309054 hasConcept C31785415 @default.
• W2149309054 hasConcept C44249647 @default.
• W2149309054 hasConcept C71924100 @default.
• W2149309054 hasConcept C90924648 @default.
• W2149309054 hasConceptScore W2149309054C126322002 @default.
• W2149309054 hasConceptScore W2149309054C141071460 @default.
• W2149309054 hasConceptScore W2149309054C207103383 @default.
• W2149309054 hasConceptScore W2149309054C2777138892 @default.
• W2149309054 hasConceptScore W2149309054C2778260677 @default.
• W2149309054 hasConceptScore W2149309054C2778715236 @default.
• W2149309054 hasConceptScore W2149309054C2779134260 @default.
• W2149309054 hasConceptScore W2149309054C2779384505 @default.
• W2149309054 hasConceptScore W2149309054C2780479503 @default.
• W2149309054 hasConceptScore W2149309054C2909675724 @default.
• W2149309054 hasConceptScore W2149309054C2911091166 @default.
• W2149309054 hasConceptScore W2149309054C31785415 @default.
• W2149309054 hasConceptScore W2149309054C44249647 @default.
• W2149309054 hasConceptScore W2149309054C71924100 @default.
• W2149309054 hasConceptScore W2149309054C90924648 @default.
• W2149309054 hasIssue "9" @default.
• W2149309054 hasLocation W21493090541 @default.
• W2149309054 hasLocation W21493090542 @default.
• W2149309054 hasOpenAccess W2149309054 @default.
• W2149309054 hasPrimaryLocation W21493090541 @default.
• W2149309054 hasRelatedWork W1815880658 @default.
• W2149309054 hasRelatedWork W2014462309 @default.
• W2149309054 hasRelatedWork W2093548935 @default.
• W2149309054 hasRelatedWork W2340045439 @default.
• W2149309054 hasRelatedWork W2576474053 @default.
• W2149309054 hasRelatedWork W2807913672 @default.

• next